Sarah Lindgreen News
-
Confidence among European chief executive officers is declining to the lowest level since the financial crisis, based on share repurchases falling to a three- year low and the disappearance of mergers and acquisitions.
-
Myriad Genetics Inc. Chief Executive Officer Pete Meldrum says his lab test to pinpoint tumors with a specific genetic mutation could have helped Sanofi-Aventis SA succeed if it had been used in a study of a drug that failed in breast cancer.
-
U.S. financial regulators are looking at specific non-bank financial companies to possibly designate them as systemically important and subject to more rigorous supervision, said Michael Gibson, director of the Division of Banking Supervision and Regulation at the Federal Reserve Board.
-
Apple Inc. and five book publishers lost their bid to have a private antitrust lawsuit over electronic book pricing dismissed.
-
The following companies may have unusual price changes in Asian trading tomorrow. Stock symbols are in parentheses, and share prices are as of the latest close. The information in each item was released after markets shut unless stated otherwise.
-
AstraZeneca Plc’s need to restock its drug pipeline and boost the lowest valuation in the pharmaceutical industry is turning companies from Amarin Corp. to Forest Laboratories Inc. into takeover candidates.
-
Pfizer Inc., the world’s biggest drugmaker, agreed to pay $60.2 million to settle foreign bribery cases it brought to U.S. authorities involving alleged payments paid by employees and agents of subsidiaries.
-
A former UBS AG client who played soccer on the Soviet national team pleaded guilty to failing to tell U.S. tax authorities about $2.6 million held in an offshore account.
-
LadaTech LLC, a biotech company partly owned by GlaxoSmithKline Plc, won a jury verdict that rival Illumina Inc. infringed a patent for gene-manipulation techniques used in diagnosing disease.
-
A combination of two AstraZeneca Plc drugs helped post-menopausal women with late-stage hormone- related breast cancer live longer and without the disease progressing compared with those taking just one of the drugs, a new study found.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page